SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
182 hedge funds and large institutions have $315M invested in SANGAMO THERAPEUTICS INC in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 63 increasing their positions, 60 reducing their positions, and 31 closing their positions.
85% more call options, than puts
Call options by funds: $1.18M | Put options by funds: $639K
1.23% more ownership
Funds ownership: 62.21% → 63.44% (+1.2%)
5% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 60
8% less funds holding
Funds holding: 197 → 182 (-15)
34% less capital invested
Capital invested by funds: $477M → $315M (-$162M)
45% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$10.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.1M |
| 3 |
BlackRock
New York
|
+$4.25M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.79M |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$2.55M |
| 2 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$2.05M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$1.83M |
| 4 |
Millennium Management
New York
|
-$1.6M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.07M |
SGMO Hedge Fund Activity: Q4 2022 in Review
182 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q4 2022, worth a combined $315M — down 34% from $477M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of SGMO and 17 opened new positions — a net loss of 14 holders — while 60 trimmed existing stakes and 63 added.
The largest buyer was State Street, adding an estimated $10.9M. The largest seller was Manulife (Manufacturers Life Insurance), cutting an estimated $2.55M.
- 182 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q4 2022, down from 197 in Q3 2022.
- Funds reported $315M of SANGAMO THERAPEUTICS INC stock for Q4 2022, down 34% quarter-over-quarter.
- 17 funds opened new SANGAMO THERAPEUTICS INC positions in Q4 2022 and 31 closed out, a net change of -14 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q4 2022 was State Street, an estimated $10.9M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q4 2022 was Manulife (Manufacturers Life Insurance), an estimated $2.55M sold.
Based on aggregated 13F filings for Q4 2022.